Assuntos
Transtorno do Espectro Autista/tratamento farmacológico , Transtornos Cromossômicos/tratamento farmacológico , Drogas em Investigação/uso terapêutico , Ética em Pesquisa , Fator de Crescimento Insulin-Like I/uso terapêutico , Seleção de Pacientes/ética , Classe Social , Justiça Social , Transtorno do Espectro Autista/economia , Criança , Deleção Cromossômica , Transtornos Cromossômicos/economia , Cromossomos Humanos Par 22 , Ensaios Clínicos Fase II como Assunto/ética , Ensaios Clínicos Controlados como Assunto/ética , Estudos Cross-Over , Método Duplo-Cego , Drogas em Investigação/economia , Geografia , Humanos , Fator de Crescimento Insulin-Like I/economiaAssuntos
Biotecnologia/economia , Biotecnologia/tendências , Indústria Farmacêutica/economia , Indústria Farmacêutica/tendências , Competição Econômica/economia , Competição Econômica/tendências , Fator de Crescimento Insulin-Like I/economia , Aprovação de Drogas/economia , Fator de Crescimento Insulin-Like I/provisão & distribuição , Estados UnidosRESUMO
Amyotrophic lateral sclerosis (ALS) is a difficult to diagnose, fatal, progressive degenerative disease with an average survival time of 2 to 5 years. Percutaneous endoscopic gastrotomy (PEG) and bi-level intermittent positive pressure (BIPAP) ventilation may be the major interventions leading to longer survival of patients with ALS. Riluzole has been shown to have modest effects on survival (as opposed to functional) gains and is currently the only drug approved for the treatment of ALS. There is conflicting evidence with regard to the ability of recombinant human insulin-like growth factor (rhIGF-I) to retard ALS progression. Mechanical ventilation (via a tracheostomy tube) is expensive, but is widely used in later stage patients with ALS in the US. A review of nine cost-effectiveness studies of riluzole and one of rhIGF-I found the following: drug costs and survival gains are the major drivers of cost effectiveness; survival gains are estimated from truncated databases with a high degree of uncertainty; more accurate stage-specific utility weights based on patients who agreed to treatment are needed; case incidence-based evaluations should be carried out; cost-effectiveness ratios are insensitive to discount rates; employment and caregiver issues or externalities have been widely ignored; threshold acceptance cost-effectiveness values are ill-defined and evaluations are not generalisable to other countries because of cost and treatment style differences. On account of the high degree of uncertainty pertaining to survival gains and the relatively high costs per life years or quality-adjusted life-years gained, and while acknowledging that not every therapy has to be cost effective (e.g. orphan drugs), it is still inconclusive as to whether or not riluzole or rhIGF-1 can be considered as cost-effective therapies for ALS.
Assuntos
Esclerose Lateral Amiotrófica/economia , Esclerose Lateral Amiotrófica/terapia , Antagonistas de Aminoácidos Excitatórios/economia , Fator de Crescimento Insulin-Like I/economia , Respiração Artificial/economia , Riluzol/economia , Esclerose Lateral Amiotrófica/diagnóstico , Análise Custo-Benefício , Custos de Medicamentos , Antagonistas de Aminoácidos Excitatórios/uso terapêutico , Previsões , Humanos , Fator de Crescimento Insulin-Like I/uso terapêutico , Anos de Vida Ajustados por Qualidade de Vida , Respiração Artificial/métodos , Riluzol/uso terapêutico , Fatores de Risco , Taxa de SobrevidaRESUMO
OBJECTIVE: Amyotrophic lateral sclerosis (ALS) is a fatal, degenerative neuromuscular disease characterised by a progressive loss of voluntary motor activity. Recombinant human insulin-like growth factor I (rhIGF-I) has been shown to be useful in treating ALS. The purpose of this study was to examine the cost effectiveness of rhIGF-I therapy in patients who have ALS. DESIGN: We performed a cost-effectiveness analysis from the societal perspective on 177 patients who received treatment with rhIGF-I or placebo in a North American randomised clinical trial. We estimated the incremental cost-effectiveness ratio of rhIGF-I using resource utilisation and functional status measurements from the clinical trial. Costs were estimated from 1996 US Medicare reimbursement schedules. Utility weights were elicited from ALS healthcare providers using the standard gamble technique. MAIN OUTCOME MEASURES AND RESULTS: The overall cost per quality-adjusted life-year (QALY) gained for rhIGF-I therapy compared with placebo was $US67,440. For the subgroups of patients who were progressing rapidly or were in earlier stages of disease at enrolment, rhIGF-I cost $US52,823 and $US43,197 per QALY gained, respectively. CONCLUSIONS: Treatment with rhIGF-I is most cost effective in ALS patients who are either in earlier stages of the disease or progressing rapidly. The cost effectiveness of rhIGF-I therapy compares favourably with treatments for other chronic progressive diseases.